L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Selon Oxfam International...l’industrie pharmaceutique empêche des millions de personnes pauvres d’avoir accès aux médicaments, mettant ainsi en péril son propre devenir...Sanofi-Aventis proposait son médicament ...Plavix à un prix 60 fois supérieur à ...[la] version générique indienne du médicament...Pfizer a ainsi intenté un procès au gouvernement des Philippines pour l’usage de clauses de sauvegarde invoquant la santé publique à l’égard du médicament Norvasc...

Línea del tiempo

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Feb 2008

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

19 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

18 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

18 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Dic 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Oxfam report "Investing for Life": Company responses

Fecha:

12 Dic 2007

Tipo de contenido:

Artículo

Idiomas disponibles: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Fecha:

27 Nov 2007

Tipo de contenido:

Artículo
Oxfam says top drug companies focusing on patents, not poor

Fecha:

26 Nov 2007

Tipo de contenido:

Artículo

Idiomas disponibles: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Fecha:

23 Nov 2007

Tipo de contenido:

Artículo

Idiomas disponibles: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Fecha:

12 Nov 2007

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Fecha:

1 Nov 2007

Tipo de contenido:

Artículo

Idiomas disponibles: English

Ver la historia completa

Cargar más Ver menos

Business & Human Rights
Resource Centre

Minerales de transición y energías renovables en los Andes

Estándares Interamericanos de Empresas y Derechos Humanos: Buzos Miskitos vs. Honduras

Actualización Semanal 18 de abril de 2024

Actualización Semanal 11 de abril de 2024

Centro de Información sobre Empresas y Derechos Humanos

Minerales de transición y energías renovables en los Andes

Estándares Interamericanos de Empresas y Derechos Humanos: Buzos Miskitos vs. Honduras

Actualización Semanal 18 de abril de 2024

Actualización Semanal 11 de abril de 2024

Esta página no está disponible en Español y está siendo mostrada en French

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Línea del tiempo

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices